Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Turkey Drives Up Worry: Global Week Ahead

18h zacks
For the Global Week Ahead, I reproduced five big Reuter’s in London world market themes. These are likely to dominate the thinking of both investors and traders.
FOX CELG FOXA

5
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

19h zacks
Ligand Pharmaceuticals, Inc. (LGND - Free Report) has announced that it will acquire U.K.’s structure-based drug discovery biotechnology company, Vernalis, for a purchase consideration of approximately $43 million. The transaction requires the company to buy all the issued and to be issued shares of Vernalis through a UK scheme of arrangement, subject to approvals of Vernalis’ shareholders.
FOX CELGZ GILD LMHA ILMN LMHB LGNDZ LGNZZ CELG LGND LGNYZ LGNXZ FOXA LM

11
Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO

2018-08-12 seekingalpha
Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments. Its most advanced candidate, toripalimab, is a PD-1 mAb whose NDA is currently being reviewed in China as a second-line treatment for melanoma. Earlier this year, the company also applied for approval to conduct clinical trials of toripalimab in the US.
MOR GILD CELG BGNE CANF

5
Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good afternoon, everyone, and welcome to Eloxx Pharmaceuticals Second Quarter 2018 Earnings Webcast and Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Ms. Barbara Ryan, Eloxx’s Investor Relations Officer. Please begin.
CELGZ CELG MDCO ELOX RDUS DTEGF DTEGY SVOND

221
Stocks To Watch: Any Privacy For Tesla?

2018-08-11 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY DCP DTK FOLD AROC ALLK CRL JWN WPZ STI-A CSCO CCB ABBV RUBY EQIX GILD CNST SYF CZR NVO JNJ MGM VRTX TM AXP NVDA BAC AGN HESM FAF KSU EFX CBU CREE LLY GSK JPM KHC TSLA PLAY DE OMP MYFW JCP TWX SYN SMLP WMT AMAT TWTR CELG WMB GSK VLKAY BAC DFS SQ IDXX BWLD ACOR STI ABBV NTAP CRNX PFE REPL JD HD WIMHY TLRY GM BMY CWH WIMHF F C ESTA A LYB CMCSA M COF WMH MRK LALWF SEMG

3
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

2018-08-11 zacks
Corcept Therapeutics Inc. (CORT - Free Report) reported adjusted second-quarter 2018 earnings of 20 cents per share, missing the Zacks Consensus Estimate of 24 cents. However, the bottom line improved from the year-ago period’s figure of 13 cents on higher revenues.
GJV NWS NWSA CORT CELG ILMN PFE

51
5 Top Stock Trades for Friday — Buy Yelp, Roku After Earnings Surge?

2018-08-09 investorplace
U.S. stocks look like they’ll eke out some gains on Thursday as equities continue to quietly grind higher. But just because the major indices barely churned out gains, doesn’t mean there was a lack of big movers during the day. Two 20% jumps highlight our top stock trades for tomorrow.
ROKU CELG TSLA

147
5 Stocks to Sell or Avoid In August

2018-08-09 investorplace
August is a tough month when it comes to investing. Many investors, traders and fund managers head for the beaches and golf courses, and volume tends to shrink because of it. We can get all sorts of frustrating price action as a result.
FB F AMD NVDA BAC WB AMZN T TWTR CELG MSFT GM INTC SNAP

4
BeiGene Reports Second Quarter 2018 Financial Results

2018-08-09 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018.
CICHY CELGZ MRTX CELG BGNE CICHF CCB 0939

2
Musk's Ambitions Rekindle Celgene Privatization Musings at RBC - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CELGZ CELG

2
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering

2018-08-08 globenewswire
BEIJING, China and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its previously announced Hong Kong initial public offering and global offering (the “Offering”) of 65,600,000 ordinary shares, par value $0.
DB CELGZ CELG BGNE MS

3
Protagonist Stock Jumps 58% After Re-Review of Test Results

2018-08-08 investorplace
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. The rally is a welcome change after months of PTGX stock going nowhere.
PFZ CELG PTGX 500680 PFE PFIZER

8
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

2018-08-08 zacks
Prothena Corporation plc (PRTA - Free Report) reported a loss of 98 cents per share for the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 88 cents and the year-ago loss of 46 cents.
ELY CELGZ GILD ICFI CELG

27
You Should Buy Sorrento Before It Reaches New Highs

2018-08-07 seekingalpha
Sorrento Therapeutics is an opportunity for investors that want a growth stock at a reasonable price.
GILD SRNE CELG

4
Biopharma 2018: Growth At A Reasonable Cost (GARC)

2018-08-07 seekingalpha
The prospects for the biopharmaceutical industry, driven by new drug discovery, are extremely attractive. I discuss below the "GARC" stocks, Gilead, Amgen, Regeneron and Celgene.
AMGN CELG BLUE

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 151020104